🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

AstraZeneca-Oxford Vaccine at 70% Efficacy

Published 11/23/2020, 03:26 AM
Updated 07/09/2023, 06:31 AM
PFE
-
AZN
-
MRNA
-
BNTX
-

Monday, November 23, 2020

Perhaps eventually someone will make a catchy marketing slogan for this time period, but for now I’ll use the term “Vaccine Monday.” For the third Monday in as many weeks, information on a Covid-19 vaccine candidate has been released, with good news once again: the joint effort between Cambridge, England-based AstraZeneca (NASDAQ:AZN) AZN and Oxford University has produced an average 70% efficacy rate in immunizing patients against Covid-19.

This, of course, follows the Pfizer PFE-BioNTech BNTX report that first claimed 90% efficacy, later revised up to 95%. Then, Cambridge, MA-based Moderna (NASDAQ:MRNA) MRNA released 94% efficacy. These are all tremendous developments in what will eventually be a post-coronavirus world. For the AstraZeneca-Oxford study, one dosing regimen also demonstrated 90% efficacy. And the one very positive piece of news from this study is that the doses may be refrigerated at normal cooler temperatures. This vaccine is also different from the other candidates, in that it is not an mRNA treatment.

So far, 23K patients have participated in the trial. It is expected to climb to 60K before the trial is completed. AstraZeneca plans to produce 3 million doses next year, provided the remainder of the trial’s checklist is satisfied. Shares of AstraZeneca are down 2% in today’s pre-market, though market indexes overall are in the green at this hour.

It’s a holiday-shortened week of trading, in what is shaping up to be the best month of trading since April for the Dow and the S&P 500. Thanksgiving on Thursday, of course, is a national holiday, and stock exchanges will close at 1pm ET Friday — in what was recently (or still is) referred to as “Black Friday.” Thus, we’ll see jobless claims data a day early this week, on Wednesday.

And, oh yeah — today’s the day to take the turkey out of the freezer!

Questions or comments about this article and/or its author? Click here>>
https://www.zacks.com/bio/mark-vickery

MARKETTINGTEXTSTART Will you retire a millionaire? MARKETTINGTEXTEND


MARKETTINGTEXTSTART One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.” MARKETTINGTEXTEND


MARKETTINGTEXTSTART Click to get it free >> MARKETTINGTEXTEND


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

BioNTech SE Sponsored ADR (NASDAQ:BNTX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.